Market Highlights
Chronic granulomatous disease (CGD) is a rare inherited immune
deficiency caused due to a random mutation in the DNA. People affected with
this disease have weakened immune systems which do not function properly. CGD
is of two types, namely, X-linked CGD and autosomal recessive type. According
to The Chronic Granulomatous Disorder Society, about 60% of people with CGD
have X-linked CGD. People with CGD generally have bacterial infections including
Salmonella, Klebsiella, Actinomyces, Streptococcus, Nocardia, and Serratia
among others. Moreover, fungal infections such as Aspergillus fumigatus and
Aspergillus nidulans are also common. The rising prevalence of rare diseases,
growing expenditure on healthcare sector in the developed economies, and
increasing research and development activities are expected to drive the growth
of the market over the forecast period. On the other hand, the expensive
diagnostic tests and treatment coupled with lack of awareness about the disease
in the developing and underdeveloped economies may hamper the market growth
over the assessment period.
The global chronic granulomatous disease market is currently dominated by many
market players. The prominent players in the market are engaged in frequent new
product launches and strategic collaborations to strengthen its market
position. Currently, Actimmune (Interferon gamma-1b) manufactured by InterMune,
Inc. is the approved by the US Food and Drug Administration (FDA) for treatment
of chronic granulomatous disease.
Segmentation
The global chronic granulomatous disease market has been
segmented into type, diagnosis, treatment, and end user.
The market, on the basis of type, is segmented into X-linked
chronic granulomatous disease and autosomal recessive chronic granulomatous
disease.
The market, by diagnosis, has been segmented into neutrophil
function tests, genetic testing, prenatal testing, and others.
The market, by treatment, has been segmented into infection
management, interferon-gamma, stem cell transplantation, and others. The
infection management segment has been further segmented into trimethoprim,
sulfamethoxazole, itraconazole, and others.
On the basis of end-user, the market has been segmented into
hospitals, clinical laboratories, and others.
https://www.marketresearchfuture.com/sample_request/6447
Regional Analysis
The market in the Americas is expected to dominate the global
chronic granulomatous disease market during the forecast period owing to the
growing prevalence of rare diseases, increasing research and development, and
presence of well-developed healthcare sector. Europe is anticipated to hold the
second largest position in the global chronic granulomatous disease market. The
market growth in this region is attributed to the rising prevalence of rare diseases
and increasing research and development activities. Asia-Pacific is expected to
be the fastest growing market owing to the developing healthcare
infrastructure, increasing awareness about rare genetic diseases, and
increasing government funding for the healthcare sector. Furthermore, the
Middle East and Africa region is expected to hold the least share in the global
market owing to the slowly developing healthcare sector especially in the
African region.
Browse
Detailed TOC with COVID-19 Impact Analysis at:
https://www.marketresearchfuture.com/reports/chronic-granulomatous-disease-market-6447
Key Players
Some of the prominent players in the global chronic
granulomatous disease market are Pfizer, Inc., InterMune, Inc., Novartis AG,
Lonza Group, GlaxoSmithKline Plc, Eli Lilly and Company, Janssen
Pharmaceuticals, Merck KGaA, Osiris Therapeutics, Inc, JCR Pharmaceuticals Co.,
Ltd., Maxcyte Inc., and Horizon Pharma Plc.
At
Market Research Future (MRFR), we enable our customers to unravel the
complexity of various industries through our Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have
supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact
us:
Market
Research Future (part of Wantstats Research and Media Private Limited),
99
Hudson Street, 5Th Floor,
New
York, New York 10013
United
States of America
+1 628
258 0071
Email:
sales@marketresearchfuture.com
0 Comments